Carcinoma, Pancreatic, CT, Neuroendocrine Tumor of Pancreas
Conditions
Brief summary
1. Imaging findings (including CT and MRI images) of both well-differentiated G3 PNET and poorly differentiated PNET were studied; 2. The CT imaging findings of G3 stage PNET and pancreatic cancer were compared to establish a Logistic regression diagnostic model, and the survival analysis of the two was compared. 3. Cox regression was used to study the risk factors for survival prognosis of well-differentiated and poorly differentiated PNET based on CT image features
Detailed description
According to the latest WHO Classification of Neuroendocrine Neoplasms (NET) in 2019, pancreatic neuroendocrine neoplasms (PNET) are divided into well-differentiated and poorly differentiated PNETs.The former is divided into G1, G2, and well differentiated G3.There are few studies on the survival outcomes of these two differentiated PNET types.The G3 imaging manifestations of the two types of differentiation have not been studied yet, and G3 PNET is often clinically misdiagnosed as pancreatic cancer, so it is necessary to differentiate the imaging manifestations and survival time of the two types. A total of 71 patients with PNET in our hospital from January 2012 to January 2019 and 58 patients with pancreatic cancer from February 2014 to August 2015 were retrospectively collected. Complete survival time data of all patients after telephone follow-up were obtained.Since G3 PNET is very rare, the investigators enrolled 9 patients with G3 PNET in the First Affiliated Hospital of Zhejiang University School of Medicine and 7 patients with G3 PNET in the Affiliated Hospital of Air Force Military Medical University from January 2013 to October 2018. CT images of PNET and pancreatic cancer were analyzed independently by two radiologists specializing in abdominal diagnosis, in which G3 lesions were evaluated simultaneously on MRI images and the others were evaluated only on CT images.Records clinical data and imaging characteristics: gender, age, tumor markers, tumor shape, size, tumor characteristics, edge, the expansion of the shrinking, pancreas, pancreatic pancreatitis, enhancement scan, arterial phase and portal phase lesions and the ratio of pancreatic parenchyma around, liver metastasis, peripheral vascular invasion, lymph node metastasis.
Interventions
OTHERNo intervention
Retrospective study without intervention
Sponsors
Zhejiang University
The First Affiliated Hospital of the Fourth Military Medical University
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Diagnosis by pathology and detailed pathological information 2. Enhanced CT examination or biopsy were performed within 2 months before surgery 3. There was no preoperative radiotherapy or chemotherapy
Exclusion criteria
1. No Ki-67 index 2. CT value cannot be measured by ROI because of pancreatic atrophy and other reasons 3. No enhanced images or missing images
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pancreatic tail contraction | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy | yes or no |
| Complicated pancreatitis | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy | yes or no |
| Tumor size | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy | Maximum surface size of the lesion (cm) |
| Tumor location | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy | Locations of the pancreas: head, neck, body and tail |
| Number of lesions | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy | Number of lesions |
| Margin | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy | well-defined or ill-defined |
| tumor texture | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy | solid；solid and cystic；complex cystic |
| Pancreatic duct/bile duct dilatation | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy | yes or no |
| Extrapancreatic tissue invasion | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy | yes or no |
| Hepatic metastasis | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy | yes or no |
| Lymphatic metastasis | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy | yes or no |
| CT value of pancreas plain scan | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy | CT value of pancreas plain scan |
| CT value of lesion plain scan | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy | CT value of lesion plain scan |
| CT value of pancreas artery phase | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy | CT value of pancreas artery phase |
| CT value of lesion artery phase | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy | CT value of lesion artery phase |
| CT value of pancreas portal phase | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy | CT value of pancreas portal phase |
| CT value of lesion portal phase | preoperative contrast-enhanced CT performed within 2 months before surgery or biopsy | CT value of lesion portal phase |
Countries
China
Outcome results
None listed